OGN Stock Analysis: Buy, Sell, or Hold?
OGN - Organon & Co.
$13.37
0.03 (0.19%)
▲
5d:
+0.34%
30d:
+45.11%
90d:
+89.31%
HOLD
MODERATE Confidence
Analysis Updated: May 13, 2026 12:00 AM ET
Earnings: May 07, 2026
0d
Smart Money Accumulation
OGN is down 7.8% this week, but smart money is accumulating calls. Top strike: $12.5 2026-06-18 with 4,182 OI. Call ratio: 75% View Scanner →
Strength: 6.4/10
Get Alerted When OGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: OGN trades at premium valuation expecting 19.0% growth. Hold existing positions but don't chase. Wait for better entry.
📊 HOLD: OGN trades at premium valuation expecting 19.0% growth. Hold existing positions but don't chase. Wait for better entry.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$10.38
Based on 5.2% avg growth
INTRINSIC VALUE TODAY
$6.44
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 2.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: OGN is currently trading at $13.37, which is considered slightly high relative to its 30-day fair value range of $8.12 to $13.45. From a valuation perspective, the stock is trading at a premium (Forward PE: 3.6) compared to its historical average (2.2). At these levels, the market is pricing in 19.0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, OGN is in a uptrend. The price is currently testing key support at $13.25. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. However, the stock is trading significantly above the average Wall Street target of $11.25. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, OGN is in a uptrend. The price is currently testing key support at $13.25. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. However, the stock is trading significantly above the average Wall Street target of $11.25. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$8.12 -
$13.45
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
54.8%
Protect Your Profits
OGN is technically overbought (RSI 77). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Trading 15.7% above Wall St target ($11.25)
- NEUTRAL: Trading at premium valuation - market expects 19.0% growth which is achievable
Trading Range Analysis
30-Day Trading Range
$8.12 -
$13.45
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$13.25
Resistance Level
$13.44
Current Trend
Uptrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
3.64
Wall Street Target
$11.25
(-15.7%)
Revenue Growth (YoY)
-3.5%
Earnings Growth (YoY)
66.7%
Profit Margin
4.0%
Valuation Premium vs History
+19.0% premium
PE vs Historical
3.6 vs 2.2
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+19.0%
(market-implied from PE analysis)
1-Year Target
$15.87
(+19%)
2-Year Target
$18.89
(+42%)
3-Year Target
$22.48
(+69%)
3-Yr Target (if PE normalizes)
(PE: 4→2)
PE COMPRESSION
$13.57
(+2%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.0, Growth: 6.4%)
$97.14
(+628%)
Base:
(SPY PE: 3.6, Growth: 6.4%)
$16.06
(+20%)
Bear:
(PE: 2.2, Growth: 6.4%)
$9.70
(-27%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (14x PE), but valuation improves significantly next year (4x PE) as earnings recover.
Trailing PE: 14.31 | Current EPS (TTM): $0.93
Bull Case
$29.28
(+120%)
Analyst growth 100.0%, PE expands to 15.7
Base Case
$26.62
(+100%)
Market implied 100.0%, PE stable at 14.3
Bear Case
$9.05
(-32%)
Severe decline -20.0%, PE contracts to 12.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: May 14, 2026 1:06 PM ET
Data refreshes hourly during market hours. Next update: 2:06 PM
Data refreshes hourly during market hours. Next update: 2:06 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
29 analysts |
$1209 | 61 BUY |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$158 | 59 HOLD |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$252 | 63 BUY |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$217 | 64 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$353 | 58 HOLD |
Advanced OGN Option Strategies
Professional options setups generated by AI based on today's OGN price and gamma walls.
